For Eniola, the strongest angle is to frame the CCT model as the core of an independent research programme in computational addiction neuroscience, leveraging his pre-registered, Bayesian-calibrated model and confirmed hypotheses to demonstrate scientific rigor and independence. This directly matches Wellcome's focus on early-career independence and health-related research, and his Nigerian nationality and enrollment in a German MSc make him eligible under the LMIC track. He should emphasize the CCT's potential to transform addiction treatment by identifying novel pharmacological targets, and position his other work (e.g., TOPOLOGIX, neurocascade) as complementary methodological expertise that strengthens his research identity.

Eligibility concern: The programme requires a PhD or equivalent; Eniola has a B.Pharm and is enrolled in an M.Sc., not yet holding a PhD. This is a critical eligibility issue. He may need to clarify if his B.Pharm plus extensive research experience counts as 'equivalent', but this is uncertain. Also, his postdoctoral experience is not clearly defined; he has been an independent researcher, which may or may not count. Additionally, he is currently enrolled in an M.Sc., which might conflict with the 'up to 3 years postdoctoral experience' requirement. Competitive disadvantage: He lacks a formal PhD and institutional affiliation, which may be viewed as a risk by reviewers. His research is highly computational and may be seen as less directly health-related unless framed carefully.